Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 9/20 | 0.60 |
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673331 | 1.00 | GPR88 (0.60) | GPR88FAAHSMN1; SMN2ACACBMAPK1 | |
| SCHEMBL30280602 | 0.90 | GPR88 (0.47) | GPR88ACACB | |
| SCHEMBL12801886 | 0.89 | GPR88 (0.54) | GPR88FAAHACACB | |
| SCHEMBL15107466 | 0.89 | GPR88 (0.54) | GPR88FAAHACACB | |
| SCHEMBL20425203 | 0.86 | GPR88 (0.44) | GPR88FAAH | |
| SCHEMBL15229037 | 0.85 | ALDH1A1 (0.48) | GPR88SMN1; SMN2 | |
| SCHEMBL2507657 | 0.84 | GPR88 (0.65) | GPR88 | |
| SCHEMBL1554282 | 0.84 | GPR88 (0.65) | GPR88 | |
| SCHEMBL2503502 | 0.84 | GPR88 (0.64) | GPR88 | |
| SCHEMBL1554164 | 0.84 | GPR88 (0.64) | GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| CN-102695546-B | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2014-09-10 | — | — | CN | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | GPR88 1678/4885FAAH 1778/4885SMN1; SMN2 4750/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | GPR88 1678/4885FAAH 1778/4885SMN1; SMN2 4750/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | GPR88 1678/4885FAAH 1778/4885SMN1; SMN2 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.